Home > Neurology > EAN 2022 > Multiple Sclerosis > Teriflunomide in children with MS: final results of TERIKIDS

Teriflunomide in children with MS: final results of TERIKIDS

Presented By
Prof. Tanuja Chitnis, Brigham and Women’s Hospital, MA, USA
Conference
EAN 2022
Trial
Phase 3, TERIKIDS
Doi
https://doi.org/10.55788/f67c9ec3
The final results of the open-label extension (OLE) period of the TERIKIDS study showed that continuous teriflunomide numerically – but not significantly – lowered the relapse risk and disability progression compared with delayed teriflunomide initiation in paediatric multiple sclerosis (MS) patients. MRI lesion count was significantly reduced and the safety profile was manageable. The beneficial effects of teriflunomide in TERIKIDS are similar to those seen in adults. Treatment of paediatric MS represents an area of unmet need, as there are limited options. The randomised, double-blind, placebo-controlled TERIKIDS study (NCT02201108), including 166 children aged 10–17 years (median age 14.6 years) with relapsing MS, showed no significant difference between teriflunomide and placebo in time to first confirmed clinical relapse after 2 years [1]. This was possibly du...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on